By Avalon Pernell August 3, 2026
BlossomHill Therapeutics Inc., a San Diego company working on precision cancer treatments, submitted its registration paperwork to the SEC on Monday, moving closer to becoming a publicly traded drugmaker.
Established in 2020, BlossomHill is developing targeted therapies for a variety of cancers. The company plans to use the net proceeds from the offering to fund clinical work on two early-stage product candidates. Those expenses are expected to consume a large portion of the capital raised, as the company has yet to produce revenue from any approved drug. Under the proposed terms, BlossomHill would sell 7.8 million shares at $15 to $17 each, seeking to raise about $132.8 million.
More than $257 million in private financing has already been invested by healthcare backers including Vivo Capital, OrbiMed, Cormorant Asset Management, and Janus Henderson Investors. The IPO is being attempted at a time when the market for new biotech listings has reopened after a prolonged downturn. In recent weeks, several other life-sciences companies have launched public offerings as investor confidence in early-stage drug developers has strengthened.
Using the $17-per-share upper end of the proposed range and the share count in its filing, the company's market capitalization would be about $494.4 million. That valuation comes as a wave of other life-sciences companies is testing the public market, with several recent offerings from early-stage drug developers.
Get the market news that matters in a five-minute read with Market Briefs, our free daily newsletter
The company's pipeline is centered on precision medicines designed to attack specific drivers of tumor growth.
Because neither candidate has reached the market, BlossomHill remains a clinical-stage biotech. For a company in that position, the IPO is not just an opportunity to raise money; it is also a test of whether investors believe the science can eventually produce a marketed therapy.
BlossomHill was established in 2020, and co-founder Peter Li previously helped build Turning Point Therapeutics, which Bristol Myers Squibb Co. acquired in 2022. The company has not generated revenue from an approved drug, and its two lead candidates remain in early-stage development. The IPO proceeds are intended to fund that clinical work.
Clinical-stage biotechs often go public before they have a product on the market, and BlossomHill is no exception. For the broader sector, a successful listing would reinforce the view that investor appetite for cancer-drug development has returned.
The financial figures in the filing show BlossomHill's losses are widening. In the quarter that ended March 31, the company recorded a net loss of $21 million, compared with a $10.5 million net loss for the same period in the previous year. The deeper loss reflects the costs of advancing drug candidates through early-stage testing.
The offering is being led by H.C. Wainwright & Co., LifeSci Capital, Guggenheim Securities, Leerink Partners, and JPMorgan Chase & Co. The company has selected BLSM as the ticker for its planned listing on the Nasdaq Global Select Market.
Join Market Briefs, our free daily newsletter, for a quick daily rundown of the markets
